Charlottesville, VIRGINIA1 Active Studies

Peripheral T-Cell Lymphoma Clinical Trials in Charlottesville, VIRGINIA

Find 1 actively recruiting peripheral t-cell lymphoma clinical trials in Charlottesville, VIRGINIA. Connect with local research sites and explore new treatment options.

1
Active Trials
1
Sponsors
50
Enrolling

Recruiting Peripheral T-Cell Lymphoma Studies in Charlottesville

About Peripheral T-Cell Lymphoma Clinical Trials in Charlottesville

Peripheral T-cell lymphomas are a diverse group of aggressive non-Hodgkin lymphomas that develop from mature T-cells. They account for about 10-15% of all NHL cases. Treatment includes combination chemotherapy, stem cell transplant, and newer targeted agents.

There are currently 1 peripheral t-cell lymphoma clinical trials recruiting participants in Charlottesville, VIRGINIA. These studies are seeking a combined 50 participants. Research is being sponsored by University of Virginia. Clinical trial participation is free and participants receive study-related medical care at no cost.

Peripheral T-Cell Lymphoma Clinical Trials in Charlottesville — FAQ

Are there peripheral t-cell lymphoma clinical trials in Charlottesville?

Yes, there are 1 peripheral t-cell lymphoma clinical trials currently recruiting in Charlottesville, VIRGINIA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Charlottesville?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Charlottesville research site will contact you about next steps.

Are clinical trials in Charlottesville free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Charlottesville studies also compensate for your time and travel.

What peripheral t-cell lymphoma treatments are being tested?

The 1 active trials in Charlottesville are testing new therapies including novel drugs, biologics, and treatment approaches for peripheral t-cell lymphoma.

Data updated March 2, 2026 from ClinicalTrials.gov